Rituximab in cutaneous B-cell lymphoma: A report of two cases

British Journal of Dermatology

Volumn 143, Issue 1, 2000, Pages 157-161

  Sabroe, R A ^a   Child, F J ^a   Woolford, A J ^a   Spittle, M F ^a   Russell Jones, R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anti CD20 monoclonal antibody therapy; Cutaneous B cell lymphoma; Rituximab

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MONOCLONAL ANTIBODY; PREDNISOLONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; FEMALE; HUMAN; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SKIN BIOPSY; SKIN LYMPHOMA; SUBCUTANEOUS NODULE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; RECURRENCE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0033929614     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03607.x     Document Type: Article

References (24)

1. McNùtt NS, Baiin AK, Placek E. B-cell lymphoma. / Dennatol Surg 0;iro/1989; 15: 716-20.
2. Willemze R. New concepts in the classification of cutaneous lymphomas. Arch Dermatol 1995; 131: 1077-80.
3. Santucci M, Pimpinelli N. Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Cancer 1991: 67: 2311-26.
4. Russell-Jones R. Spittle ME Management of cutaneous lymphoma. Baillière's Clin Haematol 1996: 9: 743-67.
5. Vermeer MH. van Geclen FAMJ. Haselen CV et al Primary cutaneous large B-cell lymphomas of the legs. Arcli Dennatol 1996: 132: 1304-8.
6. Willemze R. Kerl H. Sterry W et al EORTC classification for primarj- cutaneous lymphomas: a proposai from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer. Blood 1997: 90: 345-71.
7. Russell-Jones R. Primary cutaneous B-cell lymphoma: How useful is the new European Organization for Research and Treatment of Cancer (EORTC) classification? Br J Dermatol 1998: 139: 945-9.
8. McLaughlin P, Grillo-Lopez AJ. Link BK ft al Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. / Clin Oncol 1998; 16: 2825-33.
9. Maloney DG, Grillo-Lopez AJ, Vhite ÇA et al IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
10. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998: 10: 548-51.
11. Reff ME, Carner K, Chambers KS ft al Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45.
12. Anderson KC, Bates MP, Slaughenhoupt BL ft al Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 1984; 63: 1424-33.
13. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994: 15: 450-4.
14. Maloney DG, Smith B, Appelbaum FR. The anti-tumour effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines. Blood 1996; 88 (Suppl.): 637a(Abstr.).
15. Höchster HS, Kim KM. Green MD et al Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern cooperative oncology group study. J Clin Oncol 1992: 10: 28-32.
16. Hoffman M, Tallman MS, Hakimian D et al. 2-chIorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin's lymphoma. / C/i;i 0/iroI 1994; 12: 788-92.
17. Anonymous. Rituximab (MabThera): serious infusion-related adverse reactions. Current problems in phannacavigilaiice. London: Committee on Safety of Medicines and the Medicines Control Agency, 1999; 25 (February): 2-3.
18. Byrd JC, Waselenko JK. Maneatis TJ et al Rituximab therapy in hématologie malignancy patients with circulating blood tumour cells: association with increased infusion-related side effects and rapid blood tumor clearance. / Clin Oncol 1999; 17: 791-5.
19. Reed JC. Bcl-2 family proteins. Oncogens 1998; 17: 3225-36.
20. Adams JM. Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
21. Hermine 0, Haioun C, Lepage E et al. Prognostic significance of bd-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87: 265-72.
22. Hill ME. MacLennan KA. Cunningham DC et al Prognostic significance of bcl-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation study. Blood 1996; 88: 1046-51.
23. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicentre phase II stud)'. Blood 1998: 92: 1927-32.
24. Maloney DG, Grillo-Lopcz AJ. Bodkin DJ et al IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. / Clin Oncol 1997; 15: 3266-74.